Beyond Air Q3 Revenue Up 105% to $2.2M, Signs $32.5M NeuroNOS Deal
Beyond Air’s fiscal third-quarter revenue rose 105% year-over-year to $2.2 million, marking 21% sequential growth, while pro forma cash reached $22.3 million to fund operations into 2027. The company signed an LOI for its NeuroNOS subsidiary, potentially securing up to $32.5 million and 19.99% equity in XTL.
1. Financial Performance and Cash Runway
Beyond Air reported fiscal Q3 revenue of $2.2 million, a 105% increase year-over-year and 21% sequential gain, driven by LungFit PH sales. Pro forma cash totaled $22.3 million following a $4.5 million PIPE, providing funding into calendar 2027.
2. NeuroNOS LOI and Potential Consideration
The company signed a binding letter of intent for XTL Biopharmaceuticals to acquire 85% of its NeuroNOS subsidiary, offering up to $32.5 million in upfront, milestone payments and granting Beyond Air 19.99% equity in the combined entity.
3. Commercial Execution of LungFit PH
LungFit PH commercial momentum included the first sale to a VA Medical Center and expansion into six new countries, extending its international distribution network to 40 markets covering over three billion people.
4. Regulatory and Clinical Milestones
Beyond Air awaits FDA clearance of its second-generation LungFit PH device by year-end 2026 and will present Phase 1a UNO solid tumor data at the AACR Annual Meeting in April 2026, progressing its biopharmaceutical pipeline.